MSD has reported positive topline outcomes from the Phase III study of subcutaneous pembrolizumab in conjunction with ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...

The phase 3 trial met both primary pharmacokinetic endpoints. Topline results were announced from a phase 3 trial investigating a subcutaneous formulation of pembrolizumab, a programmed death receptor ...

The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...

Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...

US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...

Merck's (MRK) new injectable version of Keytruda aims to overcome regulatory hurdles and market challenges, offering a more ...

Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...

The #ESMOAmbassadors hashtag was used in 1,907 posts on X across the five-day congress. The 28 ESMO Ambassadors themselves ...

Drug major Pfizer Inc. (PFE) announced Wednesday the appointment of Chris Boshoff as Chief Scientific Officer and President, Research ...

Neoadjuvant immunotherapy offers a survival benefit in specific subtypes of patients but seems to offer no benefit in the ...

Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and ...